Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market.

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...

GLP-1 medications, including Zepbound and Wegovy, help regulate appetite, support weight loss and improve blood sugar. At the same time, many people experience side effects, especially when they ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

Just 20% of firms with 200 or more workers said they covered GLP-1 drugs for weight loss, according to the Peterson-KFF ...

Tirzepatide (Mounjaro, Zepbound) can help people with overweight or obesity lose weight. But how long does it take for tirzepatide to work for weight loss? There isn’t a simple answer to that. You ...

Tirzepatide starts working quickly. You might notice less hunger in a few days or weeks. Average weight loss in 3 weeks is about 8 pounds for some people. How long it takes for tirzepatide to work ...